Blueprint Medicines Corp

Blueprint Medicines — Corporate Update (April 2020)

31 slides from Blueprint Medicines's corporate update, Apr 1, 2020

  1. Slide 1: Precision That Moves: Staying one step ahead of disease

    © 2020 Blueprint Medicines Corporation R.S., living with systemic mastocytosis PRECISION THAT MOVES™ Staying one step ahead of disease APRIL 1, 2020

  2. Slide 2: Forward-looking statements

    Forward-looking statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "

  3. Slide 3: Leadership in a time of challenge and uncertainty

    Leadership in a time of challenge and uncertainty 3 PATIENT CENTERED Stay focused on the patients who need access to our innovation, perhaps now more than ever VIGILANT Constantly assess and customize approaches to potential business impacts NIMBLE Leverage global infrastructure including external c

  4. Slide 4: Clinical datasets reported in 2020 to date, with additional disclosures planned

    3 clinical datasets reported in 2020 to date, with additional disclosures planned FDA, U.S. Food and Drug Administration; ISM, indolent systemic mastocytosis; GIST, gastrointestinal stromal tumors. MTC, medullary thyroid cancer; NDA, new drug application; NSCLC, non-small cell lung cancer; PDUFA, th

  5. Slide 5: Anticipate multiple commercial launches through 2021

    1. Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutant, including PDGFRA D842V mutations. 2. Proposed MAA indication is unresectable or metastatic GIST harboring a PDGFRA D842V mutation. 3. Planned NDA or MAA submissions. MAA, marke

  6. Slide 6: 1. Unresectable or metastatic disease. 2. CStone Pharmaceuticals has exclusive rights to develop and

    1. Unresectable or metastatic disease. 2. CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains all rights in the rest of the world. 3. Approved in the U.S. for the

  7. Slide 7: Pralsetinib: an investigational precision therapy for RET-altered cancers

    Pralsetinib: an investigational precision therapy for RET-altered cancers * Planned NDA submission. Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) (CSTI). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its

  8. Slide 8: RET alterations: oncogenic drivers lacking a targeted therapeutic approach

    RET alterations: oncogenic drivers lacking a targeted therapeutic approach 1. Lipson, et al. Nat Med 2012. 2. Takeuchi, et al. Nat Med 2012. 3. Romei, et al. Oncotarget 2018. 4. Santoro, et al. J Clin Invest 1992. 5. Kato, et al. Clin Cancer Res 2017. 6. Ballerini, et al. Leukemia 2012. 8 Non-small

  9. Slide 9: Top-line ARROW trial data support registration plans for NSCLC and MTC

    Top-line ARROW trial data support registration plans for NSCLC and MTC 9 RET-altered solid tumors RET-fusion NSCLC, prior platinum Part 1 dose escalation MTC, prior MKI Part 2 expansion RET-fusion solid tumors, prior standard of care RET-mutated tumors, prior standard of care RET-altered solid tumor

  10. Slide 10: NSCLC patients with RET fusions have no highly effective treatment options

    • Chemotherapy: nonspecific, low response rates, significant toxicity • Checkpoint inhibition: Preliminary evidence for lack of benefit in RET-altered NSCLC1 • Multi-kinase inhibitors: ↓ activity, ↑ off-target toxicity2,3 • Growing understanding of RET-driven resistance • No selective RET inhibitors

  11. Slide 11: Top-line ARROW trial data: RET fusion-positive NSCLC

    Top-line ARROW trial data: RET fusion-positive NSCLC Phase 1/2 ARROW trial data in patients with RET fusion-positive NSCLC reported on January 8, 2020. Data cutoff: November 18, 2019. 1. Two responses pending confirmation. 2. All responses confirmed. DOR, duration of response; NE, not estimable. 11

  12. Slide 12: RET-altered thyroid cancer patients may benefit from highly targeted therapy

    • Multi-kinase inhibitors are approved for MTC, but have important limitations:1 • 25-44% ORR • Off-target toxicity often requiring dose modification or discontinuation • Emergence of resistance • No selective RET inhibitors are approved RET-altered thyroid cancer patients may benefit from highly ta

  13. Slide 13: Top-line ARROW trial data: RET mutant medullary thyroid cancer

    Top-line ARROW trial data: RET mutant medullary thyroid cancer Phase 1/2 ARROW trial data in patients with RET mutated MTC reported on April 1, 2020. Data cutoff: February 13, 2020. 1. One response pending confirmation. 2. All responses confirmed. 13 60% ORR1 74% ORR2 RET-mutated MTC with prior cabo

  14. Slide 14: Prolonged duration of response in patients with previously treated MTC

    Prolonged duration of response in patients with previously treated MTC Phase 1/2 ARROW trial data in patients with RET mutated MTC reported on April 1, 2020. Data cutoff: February 13, 2020. 14 100 90 80 70 60 50 40 30 20 10 0 0 3 6 9 12 15 18 21 24 Duration of response (%) Months from first document

  15. Slide 15: Top-line ARROW trial data: RET fusion-positive thyroid cancer

    Top-line ARROW trial data: RET fusion-positive thyroid cancer Phase 1/2 ARROW trial data in patients with RET fusion-positive thyroid cancer reported on April 1, 2020. Data cutoff: February 13, 2020. 1. All responses confirmed. 15 89% ORR1 RET fusion-positive thyroid cancer with prior systemic thera

  16. Slide 16: Pralsetinib is a potential best-in-class selective RET inhibitor

    Pralsetinib is a potential best-in-class selective RET inhibitor and the cornerstone of our lung cancer portfolio 1. Top-line NSCLC data reported on January 8, 2020. Data cutoff: November 18, 2020. 2. Top-line MTC data reported on April 1, 2020. Data cutoff: February 13, 2020. 3. Data reported at AS

  17. Slide 17: Avapritinib: a precision therapy with broad potential

    3L GIST 4L GIST PDGFRA exon 18 mutant GIST Avapritinib: a precision therapy with broad potential 1. Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. * Planned NDA submission. Kinome illustrati

  18. Slide 18: AYVAKIT (avapritinib) is now approved in the United States

    AYVAKIT™ (avapritinib) is now approved in the United States 18 INDICATION AYVAKIT is indicated for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations AVAILABLE DOSE STRENGTHS 100, 200 and 300 mg tablets First precision t

  19. Slide 19: Full approval of AYVAKIT based on Phase 1 NAVIGATOR trial

    Full approval of AYVAKIT based on Phase 1 NAVIGATOR trial Full prescribing information is available at www.AYVAKIT.com. CI, confidence interval. 19 EFFICACY PARAMETER PDGFRA EXON 18 (N=43) PDGFRA D842V (N=38) Overall response rate (95% CI) 84% (69%, 93%) 89% (75%, 97%) Complete response, n (%) 3 (7%

  20. Slide 20: Safety highlights from AYVAKIT prescribing information

    Safety highlights from AYVAKIT prescribing information Important safety information and full prescribing information are available at www.AYVAKIT.com. 1. Adverse reactions in 204 patients with unresectable or metastatic GIST who received 300-400 mg once daily of AYVAKIT. CNS, central nervous system.

  21. Slide 21: Systemic mastocytosis is one disease driven by KIT D816V

    Systemic mastocytosis is one disease driven by KIT D816V 21 Advanced SM Non-advanced SM (Indolent and smoldering) Requirement for life-long chronic treatment Debilitating symptoms Significant organ involvement Requirement of high intensity treatment ~75,000 patients in major markets Patient numbers

  22. Slide 22: Avapritinib is the only highly potent inhibitor of KIT D816V

    Avapritinib is the only highly potent inhibitor of KIT D816V, the common disease driver across systemic mastocytosis 1. Analysis of trial data from EXPLORER and PATHFINDER (data cutoff: August 30, 2019) and PIONEER (data cutoff: December 27, 2019). 2. Jawhar, et al. Response and progression on midos

  23. Slide 23: PIONEER trial results: unparalleled clinical profile in indolent SM

    PIONEER trial results: unparalleled clinical profile in patients with indolent SM Data reported at AAAAI Annual Meeting in March 2020. Data cutoff: December 27, 2019. 23 -5 0 -4 0 -3 0 -2 0 -1 0 0 1 0 W e e k s I S M - S A F T o t a l S y m p t o m S c o r e m e a n % c h a n g e f r o m b a s e l i

  24. Slide 24: Avapritinib improves all symptoms assessed by the ISM-SAF

    Avapritinib improves all symptoms assessed by the ISM-SAF 24 placebo avapritinib 25 mg QD Not for promotional use. Data reported at AAAAI Annual Meeting in March 2020. Data cutoff: December 27, 2019. ISM-SAF, indolent systemic mastocytosis – symptom assessment form.

  25. Slide 25: Avapritinib improves all quality of life domains measured by the MC-QoL

    Avapritinib improves all quality of life domains measured by the MC-QoL Data cutoff: December 27, 2019. MC-QoL, Mastocytosis Quality of Life Questionnaire. 25 Avapritinib 25 mg QD Placebo -38.5 -50.0 -45.5 -26.8 -0.1 1.7 12.7 -4.2 Not for promotional use.

  26. Slide 26: Avapritinib demonstrates clinically meaningful changes in disease severity

    Avapritinib demonstrates clinically meaningful changes in disease severity, as measured by the MC-QoL 1 PIONEER trial analysis of patients with MC-QoL responses at baseline and 16 weeks. Data cutoff: December 27, 2019. 2 Siebenhaar, et al. Development and Validation of the Mastocytosis Quality of Li

  27. Slide 27: Avapritinib improves objective measures of mast cell burden

    Avapritinib improves objective measures of mast cell burden assessed 27 # # # Data reported at AAAAI Annual Meeting in March 2020. Data cutoff: December 27, 2019. *Bone marrow MC assessment in SM may have variability in sampling due to patchy nature of disease. No patient on study has progressed to

  28. Slide 28: Safety results for avapritinib 25mg QD are similar to placebo at 16 weeks

    Safety results for avapritinib 25mg QD are similar to placebo at 16 weeks 28 AE in >15% of placebo or avapritinib arms avapritinib Preferred term Placebo n=9 25 mg n=10 % of subjects with ≥1 AE any grade grade 3 any grade grade 3 89 22 100 0 Nausea 22 0 10 0 Dizziness 22 0 30 0 Headache 11 0 30 0 Di

  29. Slide 29: Next steps for PIONEER trial of avapritinib in indolent SM

    Next steps for PIONEER trial of avapritinib in indolent SM 29 RP2D 25 mg QD PIONEER Registration-enabling Part 2 Planned initiation June 2020 PIONEER Dose-finding Part 1 Complete Change in ISM-SAF total symptom score PIONEER REGISTRATION-ENABLING PART 2 Design: Randomized, double-blind, placebo-cont

  30. Slide 30: EXPLORER trial results in patients with advanced SM

    • FDA breakthrough therapy designation3 • Robust activity across all disease subtypes • Median follow up of 21 months with ongoing treatment up to ~3.5 years1 EXPLORER trial results: Remarkable response rate and prolonged duration of response in patients with advanced SM 1. EXPLORER trial data repor

  31. Slide 31: Fourth quarter & full year 2019 financial results

    Fourth quarter & full year 2019 financial results 31 Balance Sheet (unaudited) FY ‘19 FY ‘18 Cash, Cash Equivalents and Investments $548.0M $494.0M Statement of Operations (unaudited) Q4 ‘19 Q4 ‘18 FY ‘19 FY ‘18 Collaboration Revenue $51.5M $1.0M $66.5M $44.5M Research & Development Expenses $88.6M

Blueprint Medicines — Corporate Update (April 2020) on 6ix